ATE346860T1 - Mutanten von streptococcaltoxinen und vefahren zu deren anwendung - Google Patents

Mutanten von streptococcaltoxinen und vefahren zu deren anwendung

Info

Publication number
ATE346860T1
ATE346860T1 AT97949752T AT97949752T ATE346860T1 AT E346860 T1 ATE346860 T1 AT E346860T1 AT 97949752 T AT97949752 T AT 97949752T AT 97949752 T AT97949752 T AT 97949752T AT E346860 T1 ATE346860 T1 AT E346860T1
Authority
AT
Austria
Prior art keywords
spe
toxin
vaccine
toxins
wild type
Prior art date
Application number
AT97949752T
Other languages
English (en)
Inventor
Patrick M Schlievert
Manuela Roggiani
Jennifer Stoehr
Douglas Ohlendorf
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE346860T1 publication Critical patent/ATE346860T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97949752T 1996-12-06 1997-12-05 Mutanten von streptococcaltoxinen und vefahren zu deren anwendung ATE346860T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3293096P 1996-12-06 1996-12-06

Publications (1)

Publication Number Publication Date
ATE346860T1 true ATE346860T1 (de) 2006-12-15

Family

ID=21867628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949752T ATE346860T1 (de) 1996-12-06 1997-12-05 Mutanten von streptococcaltoxinen und vefahren zu deren anwendung

Country Status (11)

Country Link
US (2) US6913755B2 (de)
EP (1) EP0948624B1 (de)
JP (1) JP2001505439A (de)
KR (1) KR100548663B1 (de)
CN (1) CN1211487C (de)
AT (1) ATE346860T1 (de)
AU (1) AU7625798A (de)
BR (1) BR9714641A (de)
CA (1) CA2273822A1 (de)
DE (1) DE69737032D1 (de)
WO (1) WO1998024911A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CN1211487C (zh) * 1996-12-06 2005-07-20 明尼苏达大学董事会 链球菌毒素a突变体及其使用方法
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
WO2002083169A1 (en) * 2001-04-13 2002-10-24 Idaho Research Foundation, Inc. Modified staphylococcal enterotoxins and expression systems therefore
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
CA2506538C (en) * 2001-11-26 2013-07-09 Robert G. Ulrich Bacterial superantigen vaccines
EP2537835B1 (de) * 2007-03-01 2014-04-30 Basf Se Neues Verfahren zur Herstellung von TETA über EDDN
EA201891601A1 (ru) 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
MX2020012245A (es) * 2018-05-16 2021-01-29 Univ Griffith Sindrome de choque toxico estreptococico.
EA202193121A1 (ru) 2019-05-15 2022-02-21 Неоткс Терапьютикс Лтд. Лечение рака
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172126A (en) * 1976-11-08 1979-10-23 Sankyo Company Limited Method for the inactivation of microbial toxins and attenuation of vaccines
US4784948A (en) 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US5336598A (en) 1989-11-15 1994-08-09 National Jewish Center For Immunology And Respiratory Medicine Method for diagnosing a superantigen caused pathologial condition via assay of T-cells
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
AU681341B2 (en) 1992-01-28 1997-08-28 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
EP1538208A3 (de) 1995-06-07 2007-05-23 Regents Of The University Of Minnesota Streptococcus Toxin A Mutanten und Verfahren zu deren Anwendung
CN1211487C (zh) * 1996-12-06 2005-07-20 明尼苏达大学董事会 链球菌毒素a突变体及其使用方法

Also Published As

Publication number Publication date
CN1211487C (zh) 2005-07-20
CN1246151A (zh) 2000-03-01
KR20000069316A (ko) 2000-11-25
BR9714641A (pt) 2002-01-22
US6913755B2 (en) 2005-07-05
AU7625798A (en) 1998-06-29
US20060041107A1 (en) 2006-02-23
KR100548663B1 (ko) 2006-02-03
EP0948624A2 (de) 1999-10-13
WO1998024911A3 (en) 1998-08-20
JP2001505439A (ja) 2001-04-24
WO1998024911A2 (en) 1998-06-11
US20020086813A1 (en) 2002-07-04
DE69737032D1 (de) 2007-01-11
CA2273822A1 (en) 1998-06-11
EP0948624B1 (de) 2006-11-29

Similar Documents

Publication Publication Date Title
ATE291625T1 (de) Streptococcus toxinmutanten und verfahren zu deren anwendung
ATE319830T1 (de) Mutanten von streptococcaltoxin c und verfahren zu deren anwendung
DE69636487D1 (de) Zusammensetzungen zur Immuntherapie und Diagnose von Tuberculosis
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
DE69737032D1 (de) Mutanten von streptococcaltoxinen und vefahren zu deren anwendung
DE69501591D1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE58904683D1 (de) Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
DE69940692D1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
ATE103979T1 (de) Menschliches lymphotoxin.
DE69421665D1 (de) Anomere Fluorribosylamine
EP1191096A4 (de) Neues protein und dessen dns
AU1720497A (en) Use of primers for universal fingerprint analysis
NZ335534A (en) Method of identifying potential pharmaceuticals from plant extracts

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties